Advancements in the clinical management of upper tract urothelial carcinoma

Jacob Taylor, Xiaosong Meng, Rashed Ghandour, Vitaly Margulis

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Introduction: Upper tract urothelial carcinoma (UTUC) remains a complex disease to manage given challenges in staging, surgical resection, use of perioperative therapy, and prevention of bladder recurrences. High-level evidence is limited to guide management; however, recent data have shifted treatment paradigms. We intend to review recent evidence on advancements in the clinical management for UTUC. Areas covered: This review summarizes advancements in pre-operative work-up, surgical technique, and the use of intravesical and systemic therapy in both the neoadjuvant and adjuvant settings. Special comment is made on progress in the genomics of UTUC and how that can inform clinical practice. Expert opinion: Advancements in the clinical management of UTUC are most prominently being made in the neoadjuvant chemotherapy setting. Although level I evidence is sparse, data from both single and multi-institutional retrospective studies strongly encourage the use of neoadjuvant chemotherapy especially in high-risk or advanced-stage patients.

Original languageEnglish (US)
Pages (from-to)1051-1060
Number of pages10
JournalExpert Review of Anticancer Therapy
Issue number12
StatePublished - Dec 2 2019


  • Upper tract urothelial carcinoma
  • cancer care
  • immunotherapy
  • neoadjuvant chemotherapy
  • urologic advances

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Advancements in the clinical management of upper tract urothelial carcinoma'. Together they form a unique fingerprint.

Cite this